在多发性硬化症中,从品牌转换为通用格拉蒂拉玛酸盐的耐受性和接受性
Isabella Maraffi1, Giulia Mallucci1, Giulio Disanto1
1Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6900 Lugano, Switzerland.
Journal of clinical medicine
|May 25, 2024
概括
对多发性硬化症 (MS) 转换为通用glatiramer乙酸 (GA) 是安全的,并且耐受良好. 患者报告了较少的不良事件和高的接受率与这种疾病修饰治疗的通用形式.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 多发性硬化症的治疗方法
背景情况:
- 多发性硬化症 (MS) 疾病修饰疗法 (DMT) 的成本不断上升,需要探索具有成本效益的替代方案.
- 通用药物提供了一个潜在的解决方案,以减少与MS治疗相关的医疗保健费用.
研究的目的:
- 评估从 40 mg/mL 的品牌格拉蒂拉玛酸盐 (GA) 转换到其同类药物的安全性,耐受性和患者接受度.
- 为了在MS患者中比较品牌和通用GA之间的不良事件概况.
主要方法:
- 一项前性观察性研究,涉及27名MS患者从品牌Copaxone®转换为通用Glatiramyl® 40 mg/mL.
- 在切换后的三个月内,通过视觉模拟秤收集有关局部和全身副作用和患者接受度的数据.
主要成果:
- 与品牌GA相比,通用GA显示了局部不良事件 (81.0%对96.3%) 和全身不良事件 (33.3%对59.3%) 的减少.
- 局部不良事件的强度与通用GA相比较低 (中位数为8对16).
- 71%的患者报告说,通用GA的接受率很高 (≥7/10).
结论:
- 对于患有多发性硬化症的患者来说,切换到通用glatiramer乙酸盐40 mg/mL是一种安全且耐受良好的选择.
- 患者对通用GA的接受程度很高,支持其作为品牌治疗的替代品.
相关概念视频
Phase II Reactions: Glucuronidation
386
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
386
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
189
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
189
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
286
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
286
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
198
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
198


